
CLAIMS

1. A compound of the formula:



(I),

wherein:

R_1 is halo, $-NO_2$, $alkyl_{(C\leq12)}$, substituted $alkyl_{(C\leq12)}$, $amido_{(C\leq12)}$, substituted $amido_{(C\leq12)}$, or $-NHC(O)CH(R_{1a})NH_2$, wherein:

R_{1a} is $aralkyl_{(C\leq18)}$, substituted $aralkyl_{(C\leq18)}$, or the side chain of a canonical amino acid;

R_2 is $aralkyl_{(C\leq18)}$, substituted $aralkyl_{(C\leq18)}$, $alkyl_{(C\leq12)}$ or substituted $alkyl_{(C\leq12)}$;

R_3 is $aralkyl_{(C\leq18)}$, substituted $aralkyl_{(C\leq18)}$, $alkyl_{(C\leq12)}$ or substituted $alkyl_{(C\leq12)}$;


R_4 is $alkyl_{(C\leq12)}$ or substituted $alkyl_{(C\leq12)}$;

R_5 is $-NHR_{5b}$, wherein:

R_{5b} is

$cycloalkyl_{(C\leq12)}$, $aralkyl_{(C\leq18)}$, $heteroaryl_{(C\leq12)}$, $heteroaralkyl_{(C\leq18)}$, or a substituted version of any of these groups; or

a group of the formula:



wherein:


L_1 is $-C(O)NR_{L1}-$, wherein:

R_{L1} is hydrogen, $alkyl_{(C\leq12)}$ or substituted $alkyl_{(C\leq12)}$;

$R_{5b'}$ is $aryl_{(C\leq12)}$, $aralkyl_{(C\leq18)}$, $heteroaryl_{(C\leq12)}$, $heteroaralkyl_{(C\leq18)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein the compound is further defined as:




(I),

wherein:

R_{5b} is

a group of the formula:



wherein:

L_1 is $-C(O)NR_{L1}-$, wherein:

R_{L1} hydrogen, $alkyl_{(C\leq12)}$, or substituted $alkyl_{(C\leq12)}$;

$R_{5b'}$ is $aryl_{(C\leq12)}$, $aralkyl_{(C\leq18)}$, $heteroaryl_{(C\leq12)}$, $heteroaralkyl_{(C\leq18)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 or claim 2 , wherein R_2 is 1-hydroxyethyl.

4. The compound according to any one of claims 1-3, wherein R_4 is *i*-butyl.

5. The compound according to any one of claims 1-4, wherein R_3 is 2-(naphthalen-2-yl)ethyl, *i*-butyl, or methyl.

6. The compound according to any one of claims 1-5, wherein R_{5b} is $cycloalkyl_{(C\leq12)}$ or substituted $cycloalkyl_{(C\leq12)}$.

7. The compound according to any one of claims 1-5, wherein R_{5b} is (naphthalen-2-yl)methyl, 1*H*-imidazol-2-yl, or 4-methylcyclohexyl.







8. The compound according to any one of claims 1-7, wherein $R_{5b'}$ is $heteroaryl_{(C\leq12)}$ or substituted $heteroaryl_{(C\leq12)}$.





9. The compound according to any one of claims 1-7, wherein $R_{5b'}$ is quinolin-3-yl or 1*H*-indazol-7-yl.

10. The compound according to any one of claims 1-9, wherein R_1 is $-NO_2$, $alkyl_{(C\leq12)}$, substituted $alkyl_{(C\leq12)}$, halo, $amido_{(C\leq12)}$, or substituted $amido_{(C\leq12)}$.

11. The compound according to any one of claims 1-9, wherein R_1 is methyl, halo, fluoro, iodo, or 3-aminopropanamido.


12. The compound according to claim 1, wherein the compound is further defined as:


,

,

,

,

,

,

or a pharmaceutically acceptable salt thereof.


13. The compound according to claim 1, wherein the compound is further defined as:



;

or a pharmaceutically acceptable salt thereof.


14. The compound according to claim 1, wherein the compound is further defined as:



;

or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 1, wherein the compound is further defined as:



;

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising:

a) a compound according to any one of claims 1-15; and

b) an excipient and/or a pharmaceutically acceptable carrier.

17. Use a compound or composition according to any one of claims 1-16, in the manufacture of a medicament for treating a disease or disorder.

18. The use of claim 17, wherein the compound or composition is in an amount sufficient to induce endoplasmic reticulum stress and/or shut down protein synthesis.